![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: GINS2 |
Gene summary for GINS2 |
![]() |
Gene information | Species | Human | Gene symbol | GINS2 | Gene ID | 51659 |
Gene name | GINS complex subunit 2 | |
Gene Alias | HSPC037 | |
Cytomap | 16q24.1 | |
Gene Type | protein-coding | GO ID | GO:0000724 | UniProtAcc | Q9Y248 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
51659 | GINS2 | LZE2T | Human | Esophagus | ESCC | 2.18e-04 | 5.97e-01 | 0.082 |
51659 | GINS2 | LZE7T | Human | Esophagus | ESCC | 1.16e-13 | 5.95e-01 | 0.0667 |
51659 | GINS2 | LZE22T | Human | Esophagus | ESCC | 1.57e-03 | 7.26e-01 | 0.068 |
51659 | GINS2 | LZE24T | Human | Esophagus | ESCC | 2.20e-04 | 1.39e-01 | 0.0596 |
51659 | GINS2 | LZE21T | Human | Esophagus | ESCC | 1.16e-05 | 3.55e-01 | 0.0655 |
51659 | GINS2 | LZE6T | Human | Esophagus | ESCC | 9.61e-05 | 2.09e-01 | 0.0845 |
51659 | GINS2 | P1T-E | Human | Esophagus | ESCC | 1.05e-09 | 7.00e-01 | 0.0875 |
51659 | GINS2 | P2T-E | Human | Esophagus | ESCC | 1.45e-46 | 1.09e+00 | 0.1177 |
51659 | GINS2 | P4T-E | Human | Esophagus | ESCC | 6.67e-35 | 9.78e-01 | 0.1323 |
51659 | GINS2 | P5T-E | Human | Esophagus | ESCC | 5.03e-37 | 8.74e-01 | 0.1327 |
51659 | GINS2 | P8T-E | Human | Esophagus | ESCC | 5.66e-15 | 5.34e-01 | 0.0889 |
51659 | GINS2 | P9T-E | Human | Esophagus | ESCC | 8.59e-07 | 1.91e-01 | 0.1131 |
51659 | GINS2 | P10T-E | Human | Esophagus | ESCC | 5.79e-16 | 4.81e-01 | 0.116 |
51659 | GINS2 | P11T-E | Human | Esophagus | ESCC | 6.08e-06 | 2.41e-01 | 0.1426 |
51659 | GINS2 | P12T-E | Human | Esophagus | ESCC | 4.31e-06 | 1.79e-01 | 0.1122 |
51659 | GINS2 | P15T-E | Human | Esophagus | ESCC | 1.22e-08 | 3.40e-01 | 0.1149 |
51659 | GINS2 | P16T-E | Human | Esophagus | ESCC | 2.20e-17 | 4.12e-01 | 0.1153 |
51659 | GINS2 | P17T-E | Human | Esophagus | ESCC | 9.15e-12 | 4.59e-01 | 0.1278 |
51659 | GINS2 | P19T-E | Human | Esophagus | ESCC | 6.53e-04 | 5.61e-01 | 0.1662 |
51659 | GINS2 | P20T-E | Human | Esophagus | ESCC | 8.24e-04 | 1.61e-01 | 0.1124 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Cervix | N_HPV | ![]() |
Endometrium | AEH | ![]() |
Endometrium | EEC | ![]() |
Prostate | BPH | ![]() |
Prostate | Tumor | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00062604 | Esophagus | ESCC | DNA replication | 181/8552 | 260/18723 | 3.55e-15 | 2.05e-13 | 181 |
GO:00063024 | Esophagus | ESCC | double-strand break repair | 152/8552 | 251/18723 | 1.33e-06 | 1.62e-05 | 152 |
GO:00063101 | Esophagus | ESCC | DNA recombination | 168/8552 | 305/18723 | 5.58e-04 | 3.05e-03 | 168 |
GO:00007241 | Esophagus | ESCC | double-strand break repair via homologous recombination | 79/8552 | 138/18723 | 4.05e-03 | 1.62e-02 | 79 |
GO:00007251 | Esophagus | ESCC | recombinational repair | 80/8552 | 140/18723 | 4.10e-03 | 1.63e-02 | 80 |
GO:00062603 | Oral cavity | OSCC | DNA replication | 159/7305 | 260/18723 | 3.25e-13 | 1.59e-11 | 159 |
GO:00063023 | Oral cavity | OSCC | double-strand break repair | 132/7305 | 251/18723 | 7.93e-06 | 8.52e-05 | 132 |
GO:0006310 | Oral cavity | OSCC | DNA recombination | 147/7305 | 305/18723 | 6.33e-04 | 3.56e-03 | 147 |
GO:0000725 | Oral cavity | OSCC | recombinational repair | 70/7305 | 140/18723 | 5.22e-03 | 2.03e-02 | 70 |
GO:0000724 | Oral cavity | OSCC | double-strand break repair via homologous recombination | 69/7305 | 138/18723 | 5.52e-03 | 2.14e-02 | 69 |
GO:0000727 | Oral cavity | OSCC | double-strand break repair via break-induced replication | 9/7305 | 12/18723 | 1.27e-02 | 4.24e-02 | 9 |
GO:000626011 | Oral cavity | LP | DNA replication | 97/4623 | 260/18723 | 3.67e-06 | 7.75e-05 | 97 |
GO:000630211 | Oral cavity | LP | double-strand break repair | 80/4623 | 251/18723 | 5.81e-03 | 3.46e-02 | 80 |
GO:000626012 | Skin | cSCC | DNA replication | 106/4864 | 260/18723 | 1.18e-07 | 2.77e-06 | 106 |
GO:00063025 | Skin | cSCC | double-strand break repair | 89/4864 | 251/18723 | 5.23e-04 | 3.92e-03 | 89 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
GINS2 | SNV | Missense_Mutation | rs775400601 | c.521T>C | p.Leu174Pro | p.L174P | Q9Y248 | protein_coding | tolerated(0.16) | benign(0.003) | TCGA-A2-A1G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | SD |
GINS2 | SNV | Missense_Mutation | c.544N>C | p.Ser182Pro | p.S182P | Q9Y248 | protein_coding | deleterious(0.04) | possibly_damaging(0.462) | TCGA-AD-6889-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Chemotherapy | xeloda | PD | |
GINS2 | SNV | Missense_Mutation | novel | c.251T>G | p.Phe84Cys | p.F84C | Q9Y248 | protein_coding | deleterious(0.04) | probably_damaging(0.993) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
GINS2 | SNV | Missense_Mutation | novel | c.198G>T | p.Met66Ile | p.M66I | Q9Y248 | protein_coding | deleterious(0.01) | possibly_damaging(0.719) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
GINS2 | SNV | Missense_Mutation | novel | c.291N>T | p.Lys97Asn | p.K97N | Q9Y248 | protein_coding | deleterious(0.02) | possibly_damaging(0.461) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
GINS2 | SNV | Missense_Mutation | rs371957400 | c.287N>T | p.Thr96Met | p.T96M | Q9Y248 | protein_coding | deleterious(0) | probably_damaging(0.994) | TCGA-BS-A0UM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
GINS2 | SNV | Missense_Mutation | novel | c.36N>T | p.Lys12Asn | p.K12N | Q9Y248 | protein_coding | tolerated(0.37) | benign(0.085) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
GINS2 | SNV | Missense_Mutation | novel | c.176N>T | p.Arg59Leu | p.R59L | Q9Y248 | protein_coding | deleterious(0) | benign(0.364) | TCGA-PG-A917-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
GINS2 | SNV | Missense_Mutation | novel | c.136N>A | p.Leu46Met | p.L46M | Q9Y248 | protein_coding | deleterious(0.01) | possibly_damaging(0.738) | TCGA-05-4397-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
GINS2 | SNV | Missense_Mutation | novel | c.104C>G | p.Pro35Arg | p.P35R | Q9Y248 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-BA-A4IG-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | erbitux | CR |
Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |